AU2019349780B2 - Therapeutic uses of atomic quantum clusters - Google Patents

Therapeutic uses of atomic quantum clusters Download PDF

Info

Publication number
AU2019349780B2
AU2019349780B2 AU2019349780A AU2019349780A AU2019349780B2 AU 2019349780 B2 AU2019349780 B2 AU 2019349780B2 AU 2019349780 A AU2019349780 A AU 2019349780A AU 2019349780 A AU2019349780 A AU 2019349780A AU 2019349780 B2 AU2019349780 B2 AU 2019349780B2
Authority
AU
Australia
Prior art keywords
p2394pct
nan
aqcs
cells
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019349780A
Other languages
English (en)
Other versions
AU2019349780A1 (en
Inventor
David BUCETA FERNÁNDEZ
Fernando DOMÍNGUEZ PUENTE
Manuel Arturo López Quintela
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Santiago de Compostela
Nanogap Sub NM Powder SA
Original Assignee
University of Santiago de Compostela
Nanogap Sub NM Powder SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Santiago de Compostela, Nanogap Sub NM Powder SA filed Critical University of Santiago de Compostela
Publication of AU2019349780A1 publication Critical patent/AU2019349780A1/en
Application granted granted Critical
Publication of AU2019349780B2 publication Critical patent/AU2019349780B2/en
Priority to AU2025238114A priority Critical patent/AU2025238114A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/28—Mercury; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/38—Silver; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B22—CASTING; POWDER METALLURGY
    • B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
    • B22F1/00—Metallic powder; Treatment of metallic powder, e.g. to facilitate working or to improve properties
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B22—CASTING; POWDER METALLURGY
    • B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
    • B22F1/00—Metallic powder; Treatment of metallic powder, e.g. to facilitate working or to improve properties
    • B22F1/05—Metallic powder characterised by the size or surface area of the particles
    • B22F1/054—Nanosized particles
    • C—CHEMISTRY; METALLURGY
    • C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
    • C22C—ALLOYS
    • C22C5/00—Alloys based on noble metals
    • C22C5/06—Alloys based on silver
    • C—CHEMISTRY; METALLURGY
    • C25—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES; APPARATUS THEREFOR
    • C25C—PROCESSES FOR THE ELECTROLYTIC PRODUCTION, RECOVERY OR REFINING OF METALS; APPARATUS THEREFOR
    • C25C1/00—Electrolytic production, recovery or refining of metals by electrolysis of solutions
    • C25C1/12—Electrolytic production, recovery or refining of metals by electrolysis of solutions of copper
    • C—CHEMISTRY; METALLURGY
    • C25—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES; APPARATUS THEREFOR
    • C25C—PROCESSES FOR THE ELECTROLYTIC PRODUCTION, RECOVERY OR REFINING OF METALS; APPARATUS THEREFOR
    • C25C1/00—Electrolytic production, recovery or refining of metals by electrolysis of solutions
    • C25C1/20—Electrolytic production, recovery or refining of metals by electrolysis of solutions of noble metals
    • C—CHEMISTRY; METALLURGY
    • C25—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES; APPARATUS THEREFOR
    • C25C—PROCESSES FOR THE ELECTROLYTIC PRODUCTION, RECOVERY OR REFINING OF METALS; APPARATUS THEREFOR
    • C25C5/00—Electrolytic production, recovery or refining of metal powders or porous metal masses
    • C25C5/02—Electrolytic production, recovery or refining of metal powders or porous metal masses from solutions
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B22—CASTING; POWDER METALLURGY
    • B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
    • B22F2202/00—Treatment under specific physical conditions
    • B22F2202/11—Use of irradiation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Materials Engineering (AREA)
  • Metallurgy (AREA)
  • Nanotechnology (AREA)
  • Electrochemistry (AREA)
  • Mechanical Engineering (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2019349780A 2018-09-26 2019-09-25 Therapeutic uses of atomic quantum clusters Active AU2019349780B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025238114A AU2025238114A1 (en) 2018-09-26 2025-09-29 Therapeutic uses of atomic quantum clusters

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP18196959.3 2018-09-26
EP18196963.5 2018-09-26
EP18196963 2018-09-26
EP18196959 2018-09-26
PCT/ES2019/070637 WO2020065115A2 (es) 2018-09-26 2019-09-25 Usos terapéuticos de clústeres cuánticos atómicos

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025238114A Division AU2025238114A1 (en) 2018-09-26 2025-09-29 Therapeutic uses of atomic quantum clusters

Publications (2)

Publication Number Publication Date
AU2019349780A1 AU2019349780A1 (en) 2021-03-25
AU2019349780B2 true AU2019349780B2 (en) 2025-07-03

Family

ID=68342935

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2019349780A Active AU2019349780B2 (en) 2018-09-26 2019-09-25 Therapeutic uses of atomic quantum clusters
AU2025238114A Pending AU2025238114A1 (en) 2018-09-26 2025-09-29 Therapeutic uses of atomic quantum clusters

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025238114A Pending AU2025238114A1 (en) 2018-09-26 2025-09-29 Therapeutic uses of atomic quantum clusters

Country Status (11)

Country Link
US (1) US20220031740A1 (enExample)
EP (1) EP3862109A2 (enExample)
JP (2) JP2022502450A (enExample)
KR (1) KR20210086606A (enExample)
CN (2) CN120053481A (enExample)
AU (2) AU2019349780B2 (enExample)
BR (1) BR112021005775A2 (enExample)
CA (1) CA3111915A1 (enExample)
IL (1) IL281663A (enExample)
MX (1) MX2021003566A (enExample)
WO (1) WO2020065115A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1303421C (zh) * 2004-03-24 2007-03-07 南京大学 一种用于有机氯、有机磷农药分析的同步净化提取方法
JP7595087B2 (ja) * 2020-05-09 2024-12-05 深▲セン▼深見医薬科技有限公司 非定型抗精神病薬による副作用の治療
CN111906328B (zh) * 2020-08-11 2022-10-25 苏州大学 一种177Lu标记的金纳米团簇及其制备方法和应用
JP2025034223A (ja) * 2023-08-30 2025-03-13 株式会社ハイレックスコーポレーション ワイヤロープ
WO2026124952A1 (fr) * 2024-12-13 2026-06-18 Saint-Gobain Glass France Substrat verrier antimicrobien

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1914196A1 (en) * 2005-08-03 2008-04-23 Universidade De Santiago De Compostela Stable atomic quantum clusters, production method thereof and use of same
EP2457572A1 (en) * 2010-11-05 2012-05-30 Universidade De Santiago De Compostela Use of atomic quantum clusters (aqcs) in the prevention of cell proliferative disorders, viral infections and autoimmune diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101113046A (zh) * 2006-07-25 2008-01-30 安正五 纳米胶体银水的制备方法
ES2319064B1 (es) * 2007-10-05 2010-02-15 Universidad De Santiago De Compostela Uso de clusteres cuanticos atomicos (aqcs) como antimicrobianos y biocidas.
CN101486733B (zh) * 2009-03-09 2011-05-25 华南师范大学 含氧桥双核钼原子簇化合物及其制备方法和用途
WO2015015301A2 (en) * 2013-07-31 2015-02-05 Palama Ilaria El Cancer therapy with silver nanoparticles
KR102975187B1 (ko) * 2018-06-12 2026-06-08 나노갭 서브-엔엠-파우더, 쏘시에다드 아노니마 정제된 원자 양자 클러스터를 제조하는 방법

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1914196A1 (en) * 2005-08-03 2008-04-23 Universidade De Santiago De Compostela Stable atomic quantum clusters, production method thereof and use of same
EP2457572A1 (en) * 2010-11-05 2012-05-30 Universidade De Santiago De Compostela Use of atomic quantum clusters (aqcs) in the prevention of cell proliferative disorders, viral infections and autoimmune diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BEATRIZ SANTIAGO GONZÁLEZ ET AL: "Single step electrochemical synthesis of hydrophilic/hydrophobic Ag5 and Ag6 blue luminescent clusters", NANOSCALE, vol. 4, no. 24, 1 January 2012 (2012-01-01), United Kingdom, pages 7632 *

Also Published As

Publication number Publication date
BR112021005775A2 (pt) 2021-06-29
KR20210086606A (ko) 2021-07-08
WO2020065115A3 (es) 2020-05-22
CA3111915A1 (en) 2020-04-02
JP2022502450A (ja) 2022-01-11
EP3862109A2 (en) 2021-08-11
AU2025238114A1 (en) 2025-10-23
JP2024122998A (ja) 2024-09-10
AU2019349780A1 (en) 2021-03-25
CN120053481A (zh) 2025-05-30
WO2020065115A2 (es) 2020-04-02
US20220031740A1 (en) 2022-02-03
MX2021003566A (es) 2021-08-16
IL281663A (en) 2021-05-31
CN113179632A (zh) 2021-07-27

Similar Documents

Publication Publication Date Title
US20220031740A1 (en) Therapeutic uses of atomic quantum clusters
Mao et al. Cuproptosis: mechanisms and nanotherapeutic strategies in cancer and beyond
ES2853973T3 (es) Uso de DNQ o DNQ-87 en combinación con un inhibidor de PARP1 para el tratamiento del cáncer
Brabec et al. Valuable insight into the anticancer activity of the platinum-histone deacetylase inhibitor conjugate, cis-[Pt (NH3) 2malSAHA–2H)]
HK1208365A1 (en) Use of substituted hexitols including dianhydrogalactitol and analogs to treat neoplastic disease and cancer stem cells including glioblastoma multforme and medulloblastoma
US20220265592A1 (en) Use of bipolar trans carotenoids with chemotherapy and radiotherapy for treatment of cancer
EP1677740A2 (en) Methods and compositions for treating cancer
US20060078494A1 (en) Use of inhibitors of 24-hydroxylase in the treatment of cancer
US10548893B2 (en) Inhibitors of multidrug resistance transporter P-glycoprotein
Maiti et al. Cell-specific activation of gemcitabine by endogenous H2S stimulation and tracking through simultaneous fluorescence turn-on
WO2007098719A1 (es) Combinación farmaceutica para el tratamiento y/o quimiosensibilización de tumores refractarios a drogas anticancerígenas
HK40057518A (en) Therapeutic uses of atomic quantum clusters
ES2877809T3 (es) Terapia combinada para enfermedades proliferativas
US20220396794A1 (en) APTAMERS AGAINST TRANSFERRIN RECEPTOR (TfR)
Wang et al. Repurposing antihistamine to chemotherapy via a molecular delivery platform co-targeting mitochondria and endoplasmic reticulum
US20260084978A1 (en) Process for producing atomic quantum clusters derivatives
Ballerini et al. Gasotransmitters bridging tumor biology and immunity: from pathophysiological insights to therapeutic potential
JP7461894B2 (ja) 精製された原子量子クラスターの調製方法
WO2022087173A1 (en) Phosphaplatin compounds as therapeutic agents selectively targeting highly glycolytic tumor cells and methods thereof
EP4541425A2 (en) Treating cancers with combinations of acylfulvenes with ibrutinib or bortezomib
WO2026036187A1 (en) Methods of treating cns cancers
Rizza The Roles of the Denitrosylase GSNOR in Tumor Progression.
Millard Discovery of novel small molecules targeting cancer cell metabolism

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)